INNOVATION | Ion channels in erythrocytes: A novel understanding from regulation of erythropoiesis and physiological function to diagnostic measures and therapeutic concepts

Summary
Erythrocytes represent an estimated 84% of all cells in the human body. During circulation, they experience a huge variety of physical and chemical stimulations, such as pressure, shear stress, hormones or osmolarity changes. These signals are translated into cellular responses through ion channels that modulate erythrocyte function. Ion channels in erythrocytes have only recently been recognised as the utmost important players in physiology and pathophysiology. Despite this awareness, their signalling, interactions and concerted regulation, such as the generation and effects of 'pseudo action potentials', remain elusive. INNOVATION proposes a systematic, conjoined approach using molecular biology, in vitro erythropoiesis, state-of-the-art electrophysiological techniques, methods to detect erythrocyte functionality and patient samples (channelopathies and other red blood cell-related diseases) to decipher and make use of ion channel functions in terms of disease treatment concepts. We need to overcome the challenges that hinder the gain of knowledge within the field, using genetic manipulation of progenitors, cell differentiation into erythrocytes, statistically efficient electrophysiological recordings of ion channel activity that are limited by the heterogeneity of the cell population (120 days of lifespan without any protein renewal) or access to large cohorts of patients.
Our multidisciplinary team includes biophysicists and cell biologists to investigate erythrocyte characteristics and bioengineers to develop diagnostic devices. INNOVATION involves academic research centres as well as diagnostic labs providing patient samples, blood bank research centres developing cultured transfusion products and SMEs that provide and develop diagnostic tools or innovative therapeutic red blood cell products. The consortium offers on-site training, secondments and a variety of courses in transferrable and complementary skills to 10 doctoral candidates.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/101120168
Start date: 01-09-2023
End date: 31-08-2027
Total budget - Public funding: - 2 690 092,00 Euro
Cordis data

Original description

Erythrocytes represent an estimated 84% of all cells in the human body. During circulation, they experience a huge variety of physical and chemical stimulations, such as pressure, shear stress, hormones or osmolarity changes. These signals are translated into cellular responses through ion channels that modulate erythrocyte function. Ion channels in erythrocytes have only recently been recognised as the utmost important players in physiology and pathophysiology. Despite this awareness, their signalling, interactions and concerted regulation, such as the generation and effects of 'pseudo action potentials', remain elusive. INNOVATION proposes a systematic, conjoined approach using molecular biology, in vitro erythropoiesis, state-of-the-art electrophysiological techniques, methods to detect erythrocyte functionality and patient samples (channelopathies and other red blood cell-related diseases) to decipher and make use of ion channel functions in terms of disease treatment concepts. We need to overcome the challenges that hinder the gain of knowledge within the field, using genetic manipulation of progenitors, cell differentiation into erythrocytes, statistically efficient electrophysiological recordings of ion channel activity that are limited by the heterogeneity of the cell population (120 days of lifespan without any protein renewal) or access to large cohorts of patients.
Our multidisciplinary team includes biophysicists and cell biologists to investigate erythrocyte characteristics and bioengineers to develop diagnostic devices. INNOVATION involves academic research centres as well as diagnostic labs providing patient samples, blood bank research centres developing cultured transfusion products and SMEs that provide and develop diagnostic tools or innovative therapeutic red blood cell products. The consortium offers on-site training, secondments and a variety of courses in transferrable and complementary skills to 10 doctoral candidates.

Status

SIGNED

Call topic

HORIZON-MSCA-2022-DN-01-01

Update Date

31-07-2023
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon Europe
HORIZON.1 Excellent Science
HORIZON.1.2 Marie Skłodowska-Curie Actions (MSCA)
HORIZON.1.2.0 Cross-cutting call topics
HORIZON-MSCA-2022-DN-01
HORIZON-MSCA-2022-DN-01-01 MSCA Doctoral Networks 2022